+36-1-880-8500 info@cominnex.com

Board of Directors


Ferenc Darvas, PhD


Dr. Ferenc Darvas is one of the true pioneers in the process acceleration in modern chemistry. Dr. Darvas conceived the first industrialized solution-phase combinatorial synthesis technology (CMT). This was realized by ComGenex, the first European combinatorial chemistry corporation in 1992. In the mid-90’s he focused on high-throughput ADME methodologies in combinatorial design, introduced combinatorial methodologies into chemical genomics, and recently, the use of micro- and mesoscale flow reaction technologies for combinatorial synthesis and lead optimization. Dr. Darvas is a founder of several companies including CompuDrug, ComGenex, ThalesNano, NanGenex and ComInnex.

Dr. Darvas received his first degree in organic chemistry, another in computer science, and his PhD. in the use of artificial intelligence in drug design. Dr. Darvas is co-founder of the International Society for QSAR, the Society for Biomolecular Screening (SBS), the Hungarian Chapter of the American Chemical Society and the Hungarian Biotechnology Association. He was teaching in Budapest, Barcelona, Gainesville (Florida, USA), and still teaching as guest professor at UMIT in Hall/Innsbruck, Austria.

Alex Drijver

CEO & Board Member

Alex Drijver joined as CEO in April 2015 after 7 years as CEO of ChemAxon, a leader in providing chemical software development platforms for the biotechnology and pharmaceutical industries. Mr. Drijver was a founder and former CEO of ThalesNano where he had a number of operating roles at the company between 2002 and 2007. Earlier he was Chief Financial Officer at ComGenex Inc. and Vice President of ABN AMRO Bank in London, and then Budapest.
Before joining ABN AMRO, Mr. Drijver worked in different financial and investment related positions in London for 10 years. He is the holder of the R&D 100’s Award and the Hungarian Venture Capital Association’s SME of the Year Award and served on the Board of the Pistoia Alliance (a cross industry alliance to bring down barriers to open innovation in pharmaceutical research IT) from 2010 to 2015.

Ferenc Kálmán, PhD

Board Member

Dr. Kálmán obtained his M.S. and Ph.D. degree from the Technical University of Budapest (Department of Organic Chemistry Technology). He worked 10 years for Reanal Finechemical Co. as a plant manager and later as a Director of Production and Development. He joined ComGenex in 2000 as a Director of Chemical Operations where he supervised more than 70 employees. In 2006 ComGenex was acquired by Albany Molecular Research, Inc. and he remained there for one year continuing his duties in the same position. Since 2007 he has been at Molar Chemicals Ltd as Deputy General Director where he is responsible for production, research, QC and sales. Dr. Kálmán is a certified GMP expert and he has a wide range of experience in the fields of fine chemical and pharmaceutical manufacturing, as well as in production management. He has numerous publications and several patents.